Baricitinib is an oral Janus kinase (JAK) 1/JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) …

BACKGROUND Patients with coronavirus disease 2019 (COVID-19) develop pneumonia
generally associated with lymphopenia and a severe inflammatory response due to …

Objective Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects,
we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using …

A hyperinflammatory response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …

Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no
placebo-controlled trials have focused specifically on severe/critical COVID, including …

The benefits of baricitinib in coronavirus disease‐2019 are inadequately defined. We
performed a systematic review and meta‐analysis of studies of baricitinib to determine its …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

The clinical course of coronavirus disease 2019 (Covid-19) is characterized by an initial
stage with mild symptoms of the upper respiratory tract. During this stage, the viral load of …

Background To date, only dexamethasone and tocilizumab have been shown to reduce
mortality in patients with COVID-19. Baricitinib is a Janus kinase 1/2 inhibitor with known anti …

Purpose Hyperinflammation in severe COVID-19 infection increases the risk of respiratory
failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a …